1.Graduate School, Bengbu Medical College, Anhui Province, Bengbu 233000, China;
2.Department of Nursing, the First Affiliated Hospital of Bengbu Medical College, Anhui Province, Bengbu 233000, China;
3.Department of Breast and Thyroid Surgery, Army Medical Center, Chongqing 400042, China
Abstract：Objective To explore the impact of molecular classification of breast cancer patients on post-traumatic growth (PTG). Methods This study adopted a cross-sectional survey and used convenience sampling to select 236 breast cancer patients admitted to the First Affiliated Hospital of Bengbu Medical College from January to December 2019 as the research objects. According to molecular classification, they were divided into four groups (Luminal A group, Luminal B group, human epidermal growth factor receptor 2 [HER2] positive group and triple negative group). The post-traumatic growth inventory (PTGI) was used to conduct questionnaire surveys on the four groups of breast cancer patients at the time of puncture diagnosis, one month after diagnosis, three months after diagnosis, and six months after diagnosis, the differences between the groups were compared. Results The average PTG score of breast cancer patients was (51.73±9.02), and there was no statistically significant difference in the total PTG score of the four groups at the time of puncture diagnosis (P ＞ 0.05). The total PTG scores of breast cancer patients in the Luminal B group and HER2 positive group at the time of six months after diagnosis were higher than the total PTG score at the time of diagnosis, and the differences were highly statistically significant (all P ＜ 0.01). At the time of six months after diagnosis, the total PTG score of the Luminal A group was lower than that of the Luminal B group, and the difference was highly statistically significant (P ＜ 0.01). At the time of six months after the diagnosis of breast cancer, the total PTG score of the HER2 positive group was higher than that of the triple negative group, and the difference was statistically significant (P ＜ 0.05). Conclusion The PTG levels of breast cancer patients are at a low-moderate level, and the PTG level of Luminal B and HER2 positive breast cancer patients have changed significantly after a short term. Clinical nursing practice should focus on the PTG of Luminal A and triple negative breast cancer patients.
[1] Freddie B，Jacques F，Isabelle S，et al. Global cancer statistics 2018：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J]. CA Cancer J Clin，2018，68（6）：394-424.
[2] Siegel RL，Miller KD，Jemal A. Cancer statistics，2019 [J]. CA Cancer J Clin，2019，69（1）：7-34.
[3] Marroquín B，Czamanski-Cohen J，Weihs KL，et al. Implicit loneliness，emotion regulation，and depressive symptoms in breast cancer survivors [J]. J Behav Med，2016，39（5）：832-844.
[4] Wang WT，Chang CS，Chen ST，et al. Buffering and Direct Effect of Posttraumatic Growth in Predicting Distress following Cancer [J]. Health Psychol，2017，36（6）：549-559.
[5] Perou CM，Sorlie T，Eisen MB，et al. Molecular portraits of human breast tumours [J]. Nature，2000，406（6797）：747-752.
[6] 赵毅，邓鑫.乳腺癌分子分型与治疗策略[J].中国实用外科杂志，2015，35（7）：704-708.
[7] 汪际，陈瑶，王艳波.创伤后成长评定量表的修订及信效度分析[J].护理学杂志，2011，26（14）：26-28.
[8] Coates AS，Winer EP，Goldhirsch A，et al. Tailoring therapies-improving the management of early breast cancer：St.Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015 [J]. Ann Oncol，2015，26（8）：1533-1546．
[9] 薛和玉，朱宁，曹蓉，等.乳腺癌术后辅助治疗患者心理状况现状调查[J].四川大学学报：医学版，2016，47（3）：442-444.
[10] Zhai J，Newton J，Copnell B. Posttraumatic growth experiences and its contextual factors in women with breast cancer：An integrative review [J]. Health Care Women Int，2019，40（5）：554-580.
[11] Casellas-Grau A，Ochoa C，Ruini C. Psychological and clinical correlates of posttraumatic growth in cancer：A systematic and critical review [J]. Psycho-oncology，2017，26（12）：2007-2018.
[12] 施亦佳，庄洁莲，张秋月，等.乳腺癌术后患者夫妻亲密关系在心理韧性和创伤后成长之间的中介作用[J].齐鲁护理杂志，2019，25（20）：16-19.
[13] 牛杰，崔娟，王杰敏，等.化疗期乳腺癌患者自我效能、社会支持和心理弹性对益处发现影响的路径分析[J].中国医药导报，2019，16（32）：140-143.
[14] 张婷，李惠萍，王德斌.乳腺癌患者心理韧性及影响因素分析[J].中国公共卫生，2015，31（3）：263-267.
[15] Al-Thoubaity FK. Molecular classification of breast cancer：A retrospective cohort study [J]. Ann Med Surg，2019， 49：44-48.
[16] Nguyen PL，Taghian AG，Katz MS，et al. Breast cancer subtype approximated by estrogen receptor， progesterone receptor， and HER-2 is associated with local and distant recurrence after breastconserving therapy [J]. J Clin Oncol，2008，26（14）：2373-2378.
[17] 毛洁飞，杨红健.luminal型乳腺癌新辅助内分泌治疗的研究进展[J].中华乳腺病杂志：电子版，2019，13（5）：309-312．
[18] Ponde N，Brandao M，El-Hachem G，et al. Treatment of advanced HER2-positive breast cancer：2018 and beyond [J].Cancer Treat Rev，2018，67：10-20.
[19] Pernas S，Barroso-Sousa R，Tolaney SM. Optimal treatment of early stage HER2-positive breast cancer [J]. Cancer，2018，124（23）：4455-4466.
[20] scriva-de-Romani S，Arumi M，Bellet M，et al. HER2-positive breast cancer：current and new therapeutic strategies [J]. The Breast，2018，39：80-88.
2020, Vol. 17 
京公网安备 11010502046598号